Study Finds CBD has Beneficial Effects in Patients with Schizophrenia

Cannabidiol (CBD) has beneficial effects in patients with schizophrenia, according to a new study published by the American Journal of Psychiatry

“Research in both animals and humans indicates that cannabidiol (CBD) has antipsychotic properties”, begins the study’s abstract. “The authors assessed the safety and effectiveness of CBD in patients with schizophrenia.”

In an exploratory double-blind parallel-group trial, patients with schizophrenia were “randomized in a 1:1 ratio to receive CBD (1000 mg/day; N=43) or placebo (N=45) alongside their existing antipsychotic medication.” Participants were “assessed before and after treatment using the Positive and Negative Syndrome Scale (PANSS), the Brief Assessment of Cognition in Schizophrenia (BACS), the Global Assessment of Functioning scale (GAF), and the improvement and severity scales of the Clinical Global Impressions Scale (CGI-I and CGI-S).”

Read moreStudy Finds CBD has Beneficial Effects in Patients with Schizophrenia